

Ustekinumab

Adjudication Guideline

Rule Category:
Pharmaceutical

Ref: No:
2023-PH-19

Version Control:
Version No. V5.0

Effective Date:
1st April 2023

Revision Date:
24th July 2025

Approved by:
Daman

Responsible:
Pharmaceutical
Standards
& Governance

**Related Adjudication
Guidelines:** NA

Table of Contents

1.	Abstract	3
1.1	For Members.....	3
1.2	For Medical Professionals.....	3
2.	Scope	3
3.	Adjudication Policy.....	3
3.1	Eligibility / Coverage Criteria.....	3
3.2	Requirements for Coverage	6
3.3	Non-Coverage.....	6
3.4	Payment and Coding Rules	7
4.	Denial codes	7
5.	Appendices	7
5.1	References	7
5.2	Revision History	7

1. Abstract

1.1 For Members

Ustekinumab is a biological drug that is indicated to treat autoimmune diseases such as active psoriatic arthritis, Psoriasis, Chron's disease and Ulcerative Colitis. It should be prescribed under the supervision of a specialized healthcare profession.

1.2 For Medical Professionals

Ustekinumab is a human IgG1κ monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines

2. Scope

The scope of this adjudication rule is to highlight the medical indications, and coverage details for Ustekinumab as per the policy terms and conditions of each health insurance plan administered by Daman.

3. Adjudication Policy

3.1 Eligibility / Coverage Criteria

Ustekinumab is a human interleukin-12, and -23 antagonist indicated for the treatment of:

1. **Plaque psoriasis:** Is indicated in adults, children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies with minimum body surface area involvement of 10%.
2. **Psoriatic arthritis (PsA):** Is indicated for the treatment of adult, children and adolescent patients from the age of 6 years and older with active psoriatic arthritis.
3. **Crohn's Disease:** Is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with lost response to or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies. In Crohn's disease if therapy is interrupted, resumption of treatment with subcutaneous dosing every 8 weeks is safe and effective.
4. **Ulcerative colitis:** Is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.

Pre-treatment Evaluation for Tuberculosis:

Evaluate patients for tuberculosis infection prior to initiating treatment. Do not administer Ustekinumab to patients with active tuberculosis infection. Initiate treatment of latent tuberculosis prior to administering Ustekinumab. Consider anti-tuberculosis therapy prior to initiation of Ustekinumab in patients with a history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. Closely monitor patients receiving Ustekinumab for signs and symptoms of active tuberculosis during and after treatment.

Dosage and Administration:

1. Plaque psoriasis:

- Adults recommended dosage

Weight Range (Kg)	Dose Strength	Dose Interval
Less than or equal to 100 kg	45 mg SC	1 st loading dose: Day 1 2 nd loading dose: Day 28 Maintenance: Every 12 weeks (1 st maintenance dose is after 12 weeks from the 2 nd dose)
Greater than or equal to 100 kg	90 mg SC	1 st dose: Day 1 2 nd dose: Day 28 Maintenance: every 12 weeks (1 st maintenance dose is after 12 weeks from the 2 nd dose)

- Pediatric patients (6 to 17 years old) subcutaneous recommended dosage

Weight Range (Kg)	Dose Strength	Dose Interval
Less than or equal to 60 kg	0.75 mg/kg SC	1 st dose: Day 1 2 nd dose: Day 28 Maintenance: every 12 weeks (counting should start 12 weeks from the 2 nd dose)
Greater than 60 to 100 kg	45 mg SC	1 st dose: Day 1 2 nd dose: Day 28 Maintenance: every 12 weeks (counting should start 12 weeks from the 2 nd dose)
Greater than or equal to 100 kg	90 mg SC	1 st dose: Day 1 2 nd dose: Day 28 Maintenance: every 12 weeks (counting should start 12 weeks from the 2 nd dose)

2. Psoriatic arthritis (PsA):

Condition	Dose Strength	Dose Interval
PsA with mild Psoriasis (Regardless of the weight)	45 mg SC	1 st loading dose: Day 1 2 nd loading dose: Day 28 Maintenance: Every 12 weeks (1 st maintenance dose is after 12 weeks from the 2 nd dose)
PsA with moderate to severe Psoriasis (Greater than 100 kg)	90 mg SC	1 st dose: Day 1 2 nd dose: Day 28 Maintenance: every 12 weeks (1 st maintenance dose is after 12 weeks from the 2 nd dose)

• Pediatric patients (6 to 17 years old) subcutaneous recommended dosage

Weight Range (Kg)	Dose Strength	Dose Interval
Less than or equal to 60 kg	0.75 mg/kg SC	1 st dose: Day 1 2 nd dose: Day 28 Maintenance: every 12 weeks (counting should start 12 weeks from the 2 nd dose)
Greater than 60 to 100 kg	45 mg SC	1 st dose: Day 1 2 nd dose: Day 28 Maintenance: every 12 weeks (counting should start 12 weeks from the 2 nd dose)
Greater than or equal to 100 kg	90 mg SC	1 st dose: Day 1 2 nd dose: Day 28 Maintenance: every 12 weeks (counting should start 12 weeks from the 2 nd dose)

3. Crohn's Disease and Ulcerative Colitis:

• Adults recommended dose

Weight Range (Kg)	Initial Dosage form and Strength	Maintenance Dosage form and strength	Dose Interval
up to 55 kg	260 mg IV	90 mg SC	1 st dose: Day 1 2 nd dose: Day 56 Maintenance: every 8 weeks (counting should start 8 weeks from the 2 nd dose)

Greater than 55 to 85 kg	390 mg IV	90 mg SC	1st dose: Day 1 2nd dose: Day 56 Maintenance: every 8 weeks (counting should start 8 weeks from the 2nd dose)
Greater than 85 kg	520 mg IV	90 mg SC	1st dose: Day 1 2nd dose: Day 56 Maintenance: every 8 weeks (counting should start 8 weeks from the 2nd dose)

Immunizations:

Prior to initiating therapy with Ustekinumab, patients should receive all age-appropriate immunizations as recommended by current immunization guidelines. Patients being treated with Ustekinumab should not receive live vaccines. BCG vaccines should not be given during treatment with Ustekinumab or for one year prior to initiating treatment or one year following discontinuation of treatment. Caution is advised when administering live vaccines to household contacts of patients receiving Ustekinumab because of the potential risk for shedding from the household contact and transmission to patient. Non-live vaccinations received during a course of Ustekinumab may not elicit an immune response sufficient to prevent disease.

Discontinuing treatment:

- 1. Plaque psoriasis:** Consideration should be given to discontinuing treatment in patients who have shown no response up to 28 weeks of treatment.
- 2. Psoriatic arthritis (PsA):** Consideration should be given to discontinuing treatment in patients who have shown no response up to 28 weeks of treatment.
- 3. Crohn's Disease and Ulcerative Colitis:** Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose or 16 weeks after switching to the 8-weekly maintenance dose.

3.2 Requirements for Coverage

- Failure to submit, upon request or when requesting a clinical history, indication the need for testing will result in rejection of claim.
- Kindly code the ICD-10 and the CPT codes to the highest level of specificity
- Eligible clinician specialties

Eligible clinician speciality
Dermatology
Rheumatology
Gastroenterology

3.3 Non-Coverage

- Visitor Plan
- Basic Plan as per the formulary

- Age below 6 years old

3.4 Payment and Coding Rules

Kindly apply DOH payment rules and regulations and relevant coding manuals for ICD, Drugs.

4. Denial Codes

Code	Code Description
CODE-010	Activity/diagnosis inconsistent with clinician specialty
MNEC-004	Service is not clinically indicated based on good clinical practice
MNEC-003	Service is not clinically indicated based on good clinical practice~MNEC-003
AUTH-001	Prior approval is required and was not obtained
CODE-014	Activity/diagnosis is inconsistent with the patient's age/gender~CODE-014

5. Appendices

5.1 References

https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125261s161lbl.pdf

<https://www.medicines.org.uk/emc/product/7638/smpc#gref>

https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf

5.2 Revision History

Date	Change(s)
31/03/2023	Creation of Adjudication Guideline-External Instruction Template.
05/06/2023	Update: removed colorectal surgeon
07/08/2024	Review and Edit Dosage form and strength tables
24/7/2025	AR Review-New Reference added

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.